Oral Panobinostat Plus Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Oral Panobinostat Plus Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma (PANORAMA 3): An Open-Label, Randomised, Phase 2 Study
Lancet Oncol 2020 Dec 04;[EPub Ahead of Print], JP Laubach, F Schjesvold, M Mariz, MA Dimopoulos, E Lech-Maranda, I Spicka, VTM Hungria, T Shelekhova, A Abdo, L Jacobasch, C Polprasert, R Hájek, Á Illés, T Wróbel, A Sureda, M Beksac, IZ Gonçalves, J Bladé, SV Rajkumar, A Chari, S Lonial, A Spencer, P Maison-Blanche, P Moreau, JF San-Miguel, PG RichardsonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.